Zoekresultaten - You searched for People

66 results

pi life sciences consultancy launches Music For Life-campaign to lift the taboo on young dementia

Read more

Nordic Life Science Days 2017

Read more

500 vacancies in the Flemish biotech sector

Read more

pi partners up to raise awareness on early-onset dementia

Read more

GAMIAN-Europe & CMAST announce collaborative partnership

Read more

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

Read more

Galapagos announces three new Phase 2 Proof-of-Concept studies with filgotinib

Read more

Swissmedic has accepted for review the file on Cx601 for the treatment of Crohn's disease patients

Read more

Leadership Seminar: Wednesdays in the Summer: Why DNA and Talent do matter

Read more

OLVZ Aalst User Experience Day

Read more

Mindbytes expands to North America to develop next generation serious medical games driven by artificial intelligence

Read more

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Read more

Newly described process in Parkinson’s protein as a potential new therapy route

Read more

ThromboGenics Business Update - Q3 2017

Read more

TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601

Read more

International recognition for Dirk Inzé

Read more

Celyad Announces Third Quarter 2017 Business Update

Read more

The Adecco Group Announces the Acquisition of CMAST

Read more

flanders.bio provides you with insights in the vibrant life sciences sector

Read more

Galapagos: Publication of the annual report

Read more

MDxHealth Epigenetic Biomarkers Identify Men at Increased Risk of Prostate Cancer Recurrence

Read more

Scientists expose protein responsible for allergic diseases

Read more

Galapagos increases share capital through warrant exercises

Read more

XKet4Health

Read more

3th BMIC Congress

Read more

13th International Conference on Renewable Resources & Biorefineries

Read more

Galapagos raises $338 million gross proceeds in a U.S. public offering

Read more

Galapagos announces launch of proposed public offering

Read more

REVERSED BREXIT: £250 MILLION FOR BART DE STROOPER'S DEMENTIA RESEARCH

Read more

ThromboGenics Achieves Important Milestone in the Development of THR-149

Read more

Galapagos announces closing of public offering of American Depositary Shares for gross proceeds of €363.9 million

Read more

Galapagos announces capital increase

Read more

Esperite N.V. with CryoSave contributes to treating a 9 year old child with thalassema major in Switzerland

Read more

Galapagos announces new Phase 2 Proof-of-Concept study with filgotinib in cutaneous lupus erythematosus

Read more

Nieuws van de dag - 27/04/2017

Read more

Galapagos reports first quarter 2017 results

Read more

Celyad initiates second dose escalation in THINK trial in first US patient

Read more

Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI

Read more

Galapagos presents three posters on filgotinib in Crohn's disease at DDW® 2017

Read more

VIB: Shortage of progranulin is a frequent cause of frontotemporal dementia

Read more

Galapagos NV: Seven abstracts on filgotinib accepted by EULAR 2017

Read more

Multiplicom launches complete CE-IVD marked solution in Europe for all BRCA testing needs

Read more

Helena Biosciences to develop automated blood test for chronic liver disease based on VIB and Ghent University research

Read more

Overnight skin care

Read more

Galapagos to hold Annual R&D Update 2017 on 20 June

Read more

Nieuws van de dag- 18/05/2017

Read more

Galapagos creates new warrant plan

Read more

Cochlear acquires exclusive licence to Artificial Intelligence assistant

Read more

International Course: Principles of Biosafety

Read more

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB®

Read more

TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis

Read more

Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis

Read more

Daily Newsflash- 5/07/2017

Read more

GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Read more

GREEN-CHEM: towards small footprint solutions

Read more

Genohm releases new SLIMS overview video

Read more

Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL-17C antibody MOR106 in atopic dermatitis patients

Read more

MDxhealth Enters into Distribution Agreement with Unilabs for SelectMDx for Prostate Cancer

Read more

Galapagos moving forward in CF programs at NACFC 2017

Read more

Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study

Read more

Mindbytes initiates oncology R&D program focused on patient empowerment and is selected as one of five finalists for Astellas Oncology C3 Prize®

Read more

ALBATROSS with GLPG2222 shows positive clinical results in CF patients

Read more

Galapagos initiates Phase 1 study with novel CF corrector GLPG3221

Read more

Galapagos increases share capital through warrant exercises

Read more

Galapagos to enter NASDAQ Biotech Index

Read more

Galapagos NV - Transparency notification

Read more